All In Biotech

BLA 021684 · Emd Serono

Gonal-F Rff Redi-Ject

Follitropin Alfa/Beta · Subcutaneous · Gonadotropin

Last checked: Nov 20, 2026Latest source record: May 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

May 25, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

62

13 Phase 3, 3 recruiting

FAERS reports

54

46 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 3, 2025.

GONAL-f ® RFF Redi-ject ® is a prefilled gonadotropin-containing auto-injection device indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure ( 1.1 ) Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle ( 1.2 ) 1.1 Induction of Ovulation and Pregnancy in Oligo-Anovulatory Women in whom the Cause of Infertility is Functional and Not Due to Primary Ovarian Failure. Prior to initiation of treatment with GONAL-f ® RFF Redi-ject ® : Perform a complete gynecologic and endocrinologic evaluation Exclude primary ovarian failure Exclude the possibility of pregnancy Demonstrate tubal patency Evaluate the fertility status of the male partner 1.2 Development of Multiple Follicles in Ovulatory Women as Part of an Assisted Reproductive Technology (ART) Cycle. Prior to initiation of treatment with GONAL-f ® RFF Redi-ject ® : Perform a complete gynecologic and endocrinologic evaluation, and diagnose the cause of infertility Exclude the possibility of pregnancy Evaluate the fertility status of the male partner

Mechanism: Follicle stimulating hormone (FSH), the active component in GONAL-f ® RFF Redi-ject ® , is required for normal follicular growth, follicular maturation, and gonadal steroid production. The level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching maturity. GONAL-f ® RFF Redi-ject ® stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to effect the final phase of follicle maturation, resumption of meiosis, and rupture of the follicle in the absence of an endogenous...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 900 IU/1.5ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 300 IU/0.5ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 150 IU/0.25ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • GONAL-F RFF REDI-JECT · FOLLITROPIN ALFA/BETA 450 IU/0.75ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Follitropin Alfa/Beta" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome21
  • off label use7
  • foetal exposure during pregnancy6
  • maternal exposure during pregnancy5
  • abdominal distension4
  • arnold-chiari malformation4
  • drug interaction4
  • exposure during pregnancy4
  • hyperthyroidism4
  • spina bifida4
  • dyspnoea3
  • optic nerve sheath meningioma3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20181
20194
20209
20212
20227
20239
20249
20256
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Emd Serono

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.